In late October, Morgan Stanley raised its price target on GE HealthCare from $74 to $80, citing strong order trends and backlog strength. Analysts noted a healthy demand environment based on the firm’s hospital CapEx survey, following adjustments to the company’s model after third-quarter results. Revenue for Q3 2025 reached around $5.1B, driven by Imaging, Advanced Visualization, and Pharmaceutical Diagnostics, with orders growing 6% organically. Despite margin pressures from tariffs and softness in China, guidance was positive, indicating confidence in backlog and mix. GE HealthCare Technologies Inc. (NASDAQ:GEHC) is a global medical technology company specializing in imaging, diagnostics, ultrasound, and patient monitoring. Since its spin-off from General Electric in January 2023, the company has been trading independently.

Read more at Yahoo Finance: Morgan Stanley Lifted GE HealthCare Target to $80 in Late October, Citing Strong Orders and Backlog